We’re not sure—but there are promising clues with new results expected in the coming weeks,
“This is like having gold.”
COVID-19 has revealed the extraordinary possibilities that can manifest when global scientific know-how is trained on a single topic. The virus was fully sequenced in January and a Phase 3 vaccine clinical trial is finishing in the fall.
“It feels amazing.” That's how one shipping staffer described sending out the first US COVID-19 vaccines yesterday from cargo hubs in Tennessee and Kentucky.
The US is poised to roll out millions of COVID-19 vaccine doses within days—with health workers and nursing home residents getting first dibs.
In unfair Corona where we lay our scene, one William Shakespeare humored the world when he became the UK’s second recipient of the COVID-19 vaccine. With Shakespeare clocking in at 456 years old, one couldn’t say Britain wasn't prioritizing the elderly. The web went wild…
As the UK deployed its first COVID-19 vaccines yesterday, the University of Oxford and AstraZeneca revealed that their vaccine had 70% efficacy—on average—against symptomatic illness and could substantially reduce hospitalizations,
“It’s the best early birthday present I could wish for…”
The UK vaulted over the US today in the race to immunize citizens against COVID-19 after it became the first Western country to approve the Pfizer/BioNTech vaccine under emergency authorization.
One of the biggest challenges of distributing a COVID-19 vaccine: cold storage—and one of the most promising vaccine candidates yet has particularly high maintenance requirements. Pfizer’s vaccine must be kept “colder than winter in Antarctica”: -70 degrees C to be exact…